PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|June 19, 2020
CPhI North America Canceled
Author(s)Pharmaceutical Technology Editors
The decision was made in order to give exhibitors enough time to adjust their plans in the wake of the continuing spread of COVID-19.
Advertisement
CPhI North America, organized by Informa Markets, announced on June 19, 2020 that the CPhI event, which was originally scheduled for Sept.9–11, 2020 at the Pennsylvania Convention Center in Philadelphia, PA, will be canceled. The decision was made in order to give exhibitors enough time to adjust their plans in the wake of the continuing spread of COVID-19, an Informa press release said.
“This conclusion was not one that was reached easily, but with the health and safety of our community in mind, we have made the proactive decision to act now,” the press release said. “We understand how important CPhI North America is to the industry and how much effort goes into preparing for it and so, in this difficult time, we would like to thank our community for its understanding and support.”
CPhI also announced it will host a series of webinars in place of the in-person show.
“While our live event has been cancelled, learning never stops,” the press release said. “We have a series of webinars on trending topics coming up soon, and we’ll keep you posted on the details as we finalize them.”
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement